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Abstract 
Background: Epidermal growth factor receptor (EGFR) mutations, including a known exon 19 deletion (19 del) and 
exon 21 L858R point mutation (L858R mutation), are strong predictors of the response to EGFR tyrosine kinase inhibi‑
tor (EGFR‑TKI) treatment in lung adenocarcinoma. However, whether patients carrying EGFR 19 del and L858R muta‑
tions exhibit different responsiveness to EGFR‑TKIs and what are the potential mechanism for this difference remain 
controversial. This study aimed to investigate the clinical outcomes of EGFR‑TKI treatment in patients with EGFR 19 del 
and L858R mutations and explore the genetic heterogeneity of tumors with the two mutation subtypes.
Methods: Of 1127 patients with advanced lung adenocarcinoma harboring EGFR 19 del or L858R mutations, 532 
received EGFR‑TKI treatment and were included in this study. EGFR 19 del and L858R mutations were detected by 
using denaturing high‑performance liquid chromatography (DHPLC). T790M mutation, which is a common resistant 
mutation on exon 20 of EGFR, was detected by amplification refractory mutation system (ARMS). Next‑generation 
sequencing (NGS) was used to explore the genetic heterogeneity of tumors with EGFR 19 del and L858R mutations.
Results: Of the 532 patients, 319 (60.0%) had EGFR 19 del, and 213 (40.0%) had L858R mutations. The patients with 
EGFR 19 del presented a significantly higher overall response rate (ORR) for EGFR‑TKI treatment (55.2% vs. 43.7%, 
P = 0.017) and had a longer progression‑free survival (PFS) after first‑line EGFR‑TKI treatment (14.4 vs. 11.4 months, 
P = 0.034) compared with those with L858R mutations. However, no statistically significant difference in overall 
survival (OS) was observed between the two groups of patients. T790M mutation status was analyzed in 88 patients 
before EGFR‑TKI treatment and 134 after EGFR‑TKI treatment, and there was no significant difference in the co‑exist‑
ence of T790M mutation with EGFR 19 del and L858R mutations before EGFR‑TKI treatment (5.6% vs. 8.8%, P = 0.554) 
or after treatment (24.4% vs. 35.4%, P = 0.176). In addition, 24 patients with EGFR 19 del and 19 with L858R mutations 
were analyzed by NGS, and no significant difference in the presence of multiple somatic mutations was observed 
between the two genotypes.
Conclusions: Patients with EGFR 19 del exhibit longer PFS and higher ORR compared with those with L858R muta‑
tions. Whether the heterogeneity of tumors with EGFR 19 del and L858R mutations contribute to a therapeutic 
response difference needs further investigation.
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Background
The mutation frequency of epidermal growth fac-
tor receptor (EGFR) is approximately 35%–40% among 
Asian patients with stage IV non–small cell lung cancer 
(NSCLC) [1, 2]. Mutations are the most prevalent in East 
Asian, female, non-smoking patients with adenocarcinoma 
[3]. EGFR is involved in an important signal transduction 
pathway that regulates tumorigenesis and cell survival 
and is frequently overexpressed during the development 
and progression of NSCLC. Among the various types of 
EGFR mutations, the most common genetic alterations 
are in-frame deletions of exon 19 (19 del; approximately 
44%), which encompasses the amino acids from codons 
L747 to E749, and the L858R point mutation of exon 21 
(L858R mutation; approximately 41%) [4]. Notably, the 
tyrosine kinases with EGFR exon 19 del and L858R muta-
tions exhibit a reduced affinity with adenosine triphosphate 
(ATP) but have a relatively high affinity with EGFR tyrosine 
kinase inhibitors (EGFR-TKIs) and, therefore, generate an 
antitumor effect [5, 6]. EGFR mutation status is the most 
crucial factor for NSCLC patients in the clinical response 
to EGFR-TKIs [6]. A series of phase III randomized-con-
trolled trials (RCTs) have shown that patients with EGFR-
mutated NSCLC who received EGFR-TKI treatment had a 
higher objective response rate (ORR), longer progression-
free survival (PFS), and better quality of life (QoL) than 
those who received standard chemotherapy [7–9]. How-
ever, these studies did not report an overall survival (OS) 
benefit of EGFR-TKI therapy in NSCLC patients.
Recently, a pooled analysis of two multicenter rand-
omized clinical studies (LUX-Lung 3 and LUX-Lung 6) 
compared first-line chemotherapy in patients who car-
ried EGFR mutations with afatinib, a second-generation, 
irreversible EGFR-TKI [10]. The results showed that 
patients with EGFR 19 del who received afatinib treat-
ment had a significantly longer OS compared with those 
treated with platinum-based chemotherapy. On the con-
trary, patients with L858R mutations presented longer 
OS in the chemotherapy group than in the afatinib treat-
ment group, although the difference did not reach statis-
tical significance. Thus, the researchers concluded that 
the tumors with EGFR 19 del and L858R mutations can 
be thought of as two different diseases that require differ-
ent treatment strategies. This conclusion generated great 
controversy regarding the following points: (1) whether 
the tumors with EGFR 19 del and L858R mutations are 
indeed two different diseases; (2) whether first-genera-
tion EGFR-TKIs can achieve the same results as afatinib 
in patients who possess the EGFR 19 del or L858R muta-
tions; and (3) whether the genetic heterogeneity of the 
NSCLC patients with the two genotypes is associated 
with different clinical responses to EGFR-TKIs. Provid-
ing answers to these controversies or questions would 
help optimize the individualized treatment strategies for 
advanced NSCLC.
Here, we retrospectively analyzed the efficacy of EGFR-
TKI therapy on metastatic NSCLC with an EGFR 19 del 
or an L858R mutation. Given the co-existence of uncom-
mon mutations of EGFR including T790M mutation 
and other gene mutations might influence the efficacy 
of EGFR-TKI between these two sensitive groups [11, 
12], we deeply explored the difference in heterogeneity 
between tumors with the two EGFR mutation subtypes.
Population and methods
Patient population
Among 1127 patients with histologically confirmed lung 
adenocarcinoma (stage IIIB or IV) possessing either the 
EGFR 19 del or L858R mutation treated at the Peking 
University Cancer Hospital between April 2004 and Sep-
tember 2014, 532 patients treated with EGFR-TKIs were 
included in this study. The objective response was assessed 
according to the response evaluation criteria in solid 
tumors (RECIST) 1.1 criteria [13]. Patients without meas-
urable lesions according to the RECIST 1.1 criteria were 
excluded. Informed consent to allow the use of biopsy tis-
sue for genetic analyses was obtained from all patients. 
This study was reviewed and approved by the Institutional 
Ethics Committee of Peking University Cancer Hospital.
Patient characteristics were determined by a retrospec-
tive chart review, including age at diagnosis, sex, smoking 
status, clinical stage, and Eastern Cooperative Oncology 
Group (ECOG) performance status (PS) at the initial 
treatment with EGFR-TKI and chemotherapy. Smoking 
status was based on records at the patients’ first clinic 
visit; smokers were defined as having smoked more than 
100 cigarettes in a lifetime. All patients with EGFR muta-
tions were recommended to receive gefitinib (250  mg 
daily), erlotinib (150 mg daily), or icotinib (375 mg daily) 
according to individual preference until disease progres-
sion, unacceptable toxicities, or self-withdrawal.
EGFR mutation evaluation
Tumor tissues for EGFR analysis were collected at the 
time of diagnosis or recurrence before receiving EGFR-
TKI therapy. The EGFR 19 del or L858R mutation was 
detected by using denaturing high-performance liquid 
chromatography (DHPLC) [14]. The T790M mutation 
was detected with an amplification refractory mutation 
system (ARMS) [15].
Sample collection, library preparation, 
and next‑generation sequencing
To find possible gene alterations that account for the 
potential mechanism resulting in differences in clinical 
outcome between the EGFR 19 del and L858R mutation 
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groups, we selected 12 patients with the EGFR 19 del 
(seven with paired normal leukocytes and five without) 
and another 12 patients with the L858R mutation (nine 
with paired normal leukocytes and three without) via sim-
ple random sampling. Samples of the 12 patient pairs above 
were used for next-generation sequencing (NGS) to detect 
a panel of 483 cancer-related genes, including all sites of 
EGFR mutations, other known driver genes, drug targets, 
and drug-resistant genes. Another 19 patients who were 
identified from a Novogene Company database, including 
12 patients with EGFR 19 del and 7 with L858R mutations, 
were also analyzed. Genomic DNA was extracted by using 
the Qiagen blood mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. DNA librar-
ies were prepared using the NEBNext DNA Library Prep 
Reagent Set (New England BioLabs, Ipswich, MA, USA). 
All exons of the 483 cancer-related genes and 88 introns 
from 14 genes that are frequently rearranged in cancer 
were captured using Agilent SureSelect XT (Agilent, Santa 
Clara, CA, USA). The libraries were sequenced using 
paired-end 150-bp reads on a Hiseq sequencing system 
(Illumina, Beijing, China). The median sequencing depth 
was 469× per sample (ranging from 38× to 3883×).
Statistical analysis
The Wilcoxon rank-sum test or χ2 test was used to test 
the difference of clinical and pathologic parameters 
between patients with the EGFR 19 del and L858R muta-
tions. The clinical response to EGFR-TKI treatment was 
evaluated based on computed tomography (CT) scans 
every 2  months during treatment and was classified as 
complete response (CR), partial response (PR), stable dis-
ease (SD), or progressive disease (PD) by using the stand-
ard RECIST 1.1 criteria. The ORR and disease-control 
rate (DCR) between patients with the two mutation types 
were calculated and compared by using χ2 tests. PFS was 
calculated from the start of EGFR-TKI therapy to treat-
ment failure (disease progression, death, or appearance 
of unacceptable toxicity) or the date of the last follow-
up. OS was defined as the first day of EGFR-TKI therapy 
until death from any cause or the date of the last follow-
up. Survival curves were estimated by using the Kaplan–
Meier method, and the differences between groups were 
analyzed by using the log-rank test. The multiple Cox’s 
proportional hazard model was used for univariate and 
multivariate analyses to assess the variables including 
age, sex, smoking status, PS status, EGFR mutation type, 
EGFR-TKI drugs, and treatment lines of TKI therapy and 
to predict the hazard rates for PFS and OS. The Fisher’s 
exact test was used to select the different mutations 
between the EGFR 19 del and L858R mutation single 
nucleotide variation (SNV) samples. Genes with a sig-
nificant difference in expression between the two groups 
were further analyzed. Lastly, mutation frequencies were 
used to determine whether the mutations were somatic 
or germline mutations. The statistical significance level 
was defined as two-sided P < 0.05. All statistical analyses 
were performed with the SPSS statistical software, ver-
sion 19.0 (IBM Corp., Armonk, NY, USA).
Results
Patient characteristics
Of the 532 patients with an EGFR mutation, 319 (60.0%) 
harbored an EGFR 19 del, and 213 (40.0%) had the L858R 
mutation. The patients’ clinical characteristics are shown 
Table 1 Baseline characteristics of 532 patients with non–
small cell lung cancer (NSCLC)
ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR 
epidermal growth factor receptor, TKI tyrosine kinase inhibitor
a Except for this value, other values are all presented as the number of patients
b Analyzed by using χ2 test




Exon 21 L858R 
mutation
P valueb
Total 532 319 213
Agea (years) 0.001
 Median 59 57 61
 Range 20–86 20–86 31–81
Sex 0.068
 Male 210 136 74
 Female 322 183 139
Smoking status 0.931
 Never smoker 365 220 145
 Ever smoker 145 88 57
 Unknown 22 11 11
ECOG PS 0.202
 0 117 58 59
 1 292 178 114
 2 26 15 11
 3 8 4 4
Not evaluated 89 64 25
Clinical stage 0.572
 IIIB 28 14 14
 IV 495 301 194
 Unknown 9 4 5
EGFR‑TKI 0.270
 Gefitinib 369 210 159
 Erlotinib 82 56 26
 Icotinib 56 34 22
 Unknown 25 19 6
TKI line 0.004
 Maintenance 11 1 10
 Line 1 280 157 123
 Line 2 173 118 55
 Line ≥3 60 36 24
 Unknown 8 7 1
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in Table 1. The median age of the patients was 59 years 
(range, 20–86  years); the majority of patients were 
women (60.5%) and non-smokers (68.6%). There were 
369 patients (69.4%) who received gefitinib, 82 patients 
(15.4%) who received erlotinib, 56 patients (10.5%) who 
received icotinib, and 25 patients (4.7%) who could not 
be verified. All 532 NSCLC patients were treated with 
EGFR-TKIs; among these patients, 280 (52.6%) received 
EGFR-TKIs as a first-line therapy, 233 (43.8%) as a sec-
ond-line therapy or greater, 11 (2.1%) as a maintenance 
therapy, and 8 (1.5%) of which could not be verified in 
this regard.
Objective response
Of the 532 patients, 79 were excluded due to the lack of 
response evaluation, and the other 453 were divided into 
two groups according to the EGFR 19 del and L858R 
mutation statuses (Table  2). The clinical responses, 
including CR, PR, SD, and PD, did not significantly dif-
fer between the two groups (P =  0.074). For the whole 
cohort, the ORR of TKIs in patients with the EGFR 19 
del was significantly higher than that in patients with the 
L858R mutation (55.2% vs. 43.7%, P = 0.017). There was 
no significant difference in the DCR between 19 del and 
L858R mutation groups (94.1% vs. 89.6%, P = 0.081). In 
the stratified analysis, the EGFR 19 del group displayed 
higher ORR to gefitinib than the L858R mutation group 
(59.2% vs. 43.2%, P = 0.005). However, no significant dif-
ferences were observed in patients treated with erlotinib 
(55.8% vs. 39.1%, P = 0.184) or icotinib (33.3% vs. 58.8%, 
P = 0.089).
Progression‑free survival
Up to the last follow-up in September 2014, the median 
PFS in the entire cohort was 12.5  months (95% con-
fidence interval [CI], 11.2–13.7  months). In patients 
treated with a TKI as the first-line therapy, the patients 
with EGFR 19 del had significantly longer PFS compared 
with those with L858R mutation (14.4 vs. 11.4  months, 
P  =  0.034; Fig.  1a). There was no significant difference 
in PFS between the two groups with TKI as second-
line therapy or greater (11.7 vs. 11.2 months, P = 0.371; 
Fig. 1b).
We subsequently analyzed whether there was a differ-
ence in PFS between patients with the same mutation 
subtype (the EGFR 19 del or L858R mutation) receiving 
different EGFR-TKI agents. No significant differences 
were observed between every two agents. Further, we 
investigated whether the same EGFR-TKI agent has dif-
ferent effects on patients with different mutation sub-
types. In the first-line therapeutic setting of EGFR-TKIs, 
gefitinib could provide the patients harboring EGFR 
19 del with a significantly longer PFS compared with 
those carrying L858R mutations (13.2 vs. 10.0  months, 
P = 0.008). In addition, this trend of prolonged PFS was 
also observed in the subgroup that received erlotinib as 
a first-line therapy, although the difference did not reach 
statistical significance (19.4 vs. 11.4 months, P = 0.889).
Stepwise Cox proportional hazards analysis was car-
ried out to evaluate the association between PFS and the 
clinical characteristics described above. For patients with 
EGFR mutations who received TKI as a first-line therapy, 
both univariate and multivariate analysis showed that 
EGFR mutation status was the only predictive factor for 
PFS (P = 0.035 and P = 0.017, respectively), as shown in 
Table 3.
Overall survival analysis
The median OS for the entire cohort was 31.3  months 
(95% CI, 26.8–35.7  months). There was no significant 
difference in median OS between the EGFR 19 del and 
L858R mutation groups with first-line TKI treatment 
(34.9 vs. 37.5  months, P  =  0.566; Fig.  2a) or second-
line or greater TKI treatment (26.7 vs. 23.8  months, 
P =  0.256; Fig.  2b). Multivariate analysis did not reveal 
any predictive factor for OS, as shown in Table 3.
Table 2 Response to  EGFR-TKIs in  453 NSCLC patients 
with different EGFR genotypes
CR complete response, PR partial response, SD stable disease, PD progressive 
disease, ORR objective response rate, ORR = CR + PR, DCR disease control 
rate, DCR = CR + PR + SD, MDT median duration of treatment, ECOG Eastern 
Cooperative Oncology Group, PS performance status, EGFR epidermal growth 
factor receptor, TKI tyrosine kinase inhibitor
a Analyzed by using χ2 test
Variate Exon 19 deletion 
(n = 270)
Exon 21 L858R 
mutation (n = 183)
P valuea
Best response (cases) 0.074
 CR 4 2
 PR 145 78
 SD 105 84
 PD 16 19
MDT (months)
 CR/PR 13.0 14.6 0.874
 SD 13.7 11.9 0.193
ORR (%)
 Total 55.2 43.7 0.017
 Line 1 60.0 49.5 0.108
 Line ≥ 2 49.6 32.4 0.018
 Gefitinib 59.2 43.2 0.005
 Erlotinib 55.8 39.1 0.184
 Icotinib 33.3 58.8 0.089
DCR (%)
 Total 94.1 89.6 0.081
 Line 1 96.2 92.4 0.208
 Line ≥2 91.7 84.5 0.113
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Association of the EGFR mutations with the T790M 
mutation
The T790M mutation status is shown in Table 4 accord-
ing to different EGFR genotypes and TKI therapy. The 
frequency of the T790M mutation in the post-EGFR-
TKI treatment group was significantly higher than that 
in the pre-EGFR-TKI treatment group (28.4% vs. 6.8%, 
P  <  0.001), and the co-existence of T790M mutation 
with EGFR 19 del in pre- and post-EGFR-TKI treatment 
groups was lower than that with the L858R mutation, but 
this difference was not statistically significant (5.6% vs. 
8.8%, P = 0.554; 24.4% vs. 35.4%, P = 0.176, respectively).
Association of the EGFR mutations with the multi‑genes 
aberrances
In total, 43 patients were involved in our genetic hetero-
geneity analysis, and there was no significant difference 
in the distribution of 483 cancer-related genes between 
the EGFR 19 del and L858R mutation groups. Twelve 
patient pairs from our center with relatively complete 
Fig. 1 Progression‑free survival (PFS) curves of epidermal growth factor receptor (EGFR)‑mutated patients treated with tyrosine kinase inhibitors 
(TKIs). a PFS curves of patients with the EGFR exon 19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation) who received first‑line 
TKI therapy (14.4 vs. 11.4 months, P = 0.034); b PFS curves of patients with the EGFR 19 del and L858R mutation who received second‑line or greater 
TKI therapy (11.7 vs. 11.2 months, P = 0.371)
Table 3 Univariate and multivariate analyses for the PFS and OS of patients with tissue detected mutation and the use 
of TKIs as first-line therapy
PFS progression-free survival, OS overall survival, HR hazard ratio, 95% CI 95% confidence interval, ECOG Eastern Cooperative Oncology Group, PS performance status, 
EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor
a Analyzed by using univariate and multivariate COX regression adjusted for age, sex, smoking status, ECOG PS, EGFR-TKIs, and stage
Variable PFS OS
Univariate Multivariate Univariate Multivariate
HR (95% CI) P valuea HR (95% CI) P valuea HR (95% CI) P valuea HR (95% CI) P valuea
Age 1.000 (0.986–1.014) 0.980 0.993 (0.977–1.009) 0.381 1.008 (0.987–1.029) 0.480 0.996 (0.973–1.020) 0.757
Sex (men vs. women) 1.149 (0.830–1.590) 0.404 1.520 (0.916–2.522) 0.105 1.540 (0.992–2.393) 0.055 1.776 (0.890–3.544) 0.103
Smoking status (ever vs. 
never)
0.907 (0.628–1.311) 0.604 0.616 (0.363–1.044) 0.072 1.299 (0.807–2.091) 0.282 0.835 (0.405–1.722) 0.626
ECOG PS (2 vs. 0‑1) 0.969 (0.523–1.796) 0.921 1.019 (0.536–1.935) 0.955 1.054 (0.454–2.447) 0.903 1.281 (0.531–3.091) 0.582
EGFR‑TKI (erlotinib vs. 
gefitinib)
0.828 (0.531–1.291) 0.405 0.765 (0.448–1.307) 0.327 1.862 (0.581–5.962) 0.295 0.756 (0.357–1.603) 0.466
EGFR‑TKI (icotinib vs. 
gefitinib)
0.652 (0.359–1.184) 0.160 0.702 (0.362–1.361) 0.295 1.917 (0.551–6.664) 0.306 0.255 (0.063–1.037) 0.056
Stage (IIIB vs. IV) 0.552 (0.203–1.498) 0.243 0.402 (0.119–1.356) 0.142 0.878 (0.276–2.795) 0.826 0.600 (0.144–2.506) 0.483
EGFR mutation (exon 19 
del vs. L858R mutation)
0.705 (0.509–0.976) 0.035 0.631 (0.432–0.920) 0.017 0.878 (0.563–1.370) 0.566 0.671 (0.397–1.133) 0.135
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clinical information were further analyzed (Fig. 3). There 
were 20 different SNV/InDels (insertions/deletions) 
identified in the tumor tissue samples from the 12 patient 
pairs with an EGFR 19 del or L858R mutation (P < 0.05; 
Table  5). Except for EGFR mutations, the mutation fre-
quency for the rest 19 differential SNV/InDels approxi-
mately equaled 50% or 100%, and these SNV/InDels were 
found in the tumor tissues of patients whose correspond-
ing leukocytes were not sequenced due to the deficiency 
of the samples. Considering the genetic constitution of 
diploid organisms, we believed that these mutations were 
germline mutations rather than somatic ones. Therefore, 
the NGS analysis of the small samples did not display 
the difference in the somatic mutations between the two 
genotypes. The copy number variation of myeloid cell 
leukemia sequence 1 (MCL1) occurs more frequently 
in patients with an EGFR 19 del (10 of 12 patients) 
compared with those with the L858R mutation (4 of 
12 patients); this difference was significant (P  =  0.040; 
Fig. 4).
Discussion
The current study retrospectively investigated the clinical 
outcomes of 532 lung adenocarcinoma patients harbor-
ing EGFR 19 del or L858R mutation after first-generation 
EGFR-TKI treatment. The ORR was significantly higher 
in the EGFR 19 del group than in the L858R mutation 
group. When EGFR-TKI was used as a first-line treat-
ment, the patients with the EGFR 19 del presented signif-
icantly longer PFS compared with those with the L858R 
mutation. However, no significant difference of OS 
between the two mutated subgroups was observed. Either 
gefitinib or erlotinib therapy provided the patients car-
rying an EGFR 19 del with a longer PFS than those with 
L858R mutations, although the difference in the erlotinib 
group did not reach statistical significance. These results 
suggested that PFS differences in the response to EGFR-
TKI therapy between the patients with EGFR 19 del and 
L858R mutations may mainly derive from gefitinib and 
erlotinib therapy. However, this theory requires addition 
studies for confirmation.
The NGS technique was used in 43 patients with the 
EGFR 19 del or L858R mutation for genetic heteroge-
neity analysis. We found that there was no difference in 
uncommon EGFR mutations or other somatic mutations 
between the two mutation subtypes. However, accord-
ing to our data and those of other investigators, patients 
with the EGFR 19 del indeed exhibited a longer PFS than 
patients with the L858R mutation [7–9]. Possible reasons 
resulting in the difference in PFS were speculated to be 
related to the space structure, different drug affinity with 
Fig. 2 Overall survival (OS) curves of EGFR‑mutated patients treated with TKIs. a OS curves of patients with EGFR 19 del and L858R mutation who 
received first‑line TKI therapy (34.9 vs. 37.5 months, P = 0.566); b OS curves of patients with the EGFR 19 del and L858R mutation who received 
second‑line or greater TKI therapy (26.7 vs. 23.8 months, P = 0.256)
Table 4 Difference of  co-existence of  T790M mutation 
between patients with EGFR 19 del and L858R mutation
a By using χ2 test. All values are presented as the number of patients followed 
by the percentage in the parentheses
Patient Exon 19  
deletion




T790M mutation pre‑TKI 0.554
 Positive 3 (5.6) 3 (8.8)
 Negative 51 (94.4) 31 (91.2)
T790M mutation post‑TKI 0.176
 Positive 21 (24.4) 17 (35.4)
 Negative 65 (75.6) 31 (64.6)
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EGFR-TKIs, and genetic heterogeneity between these 
two genotypes [16, 17].
First, just like the tyrosine kinases of sensitive EGFR 
mutations exhibit a relatively higher affinity with EGFR-
TKIs compared with the affinity with ATP, EGFR 19 del 
might be efficiently inhibited by EGFR-TKIs compared 
with the L858R mutation [5]. We assume that EGFR 
structural alterations caused by the EGFR 19 del may lead 
to a tighter combination with EGFR-TKIs compared with 
those changes caused by the L858R mutation. However, 
in vitro studies have demonstrated that NSCLC cell lines 
that possess the EGFR 19 del and L858R mutation had 
a similar degree of EGFR phosphorylation and almost 
equally growth inhibited by equivalent concentration of 
gefitinib [18, 19]. As a consequence, it is now unknown 
whether different conformations and/or affinities with 
EGFR-TKIs between EGFR 19 del and L858R mutations 
provide an explanation for the difference in survival. 
These issues still need further study.
Second, the influence of genetic heterogeneity in 
EGFR-mutated tumors on the response to EGFR-TKI 
treatment has been confirmed by several studies. Pre-
vious studies have reported that the T790M mutation, 
which is associated with an acquired resistance to revers-
ible EGFR-TKIs [20, 21], might occur more frequently 
in patients harboring the L858R mutation than in those 
with an EGFR 19 del [11]. Furthermore, the co-existence 
of EGFR 19 del or L858R mutations with other mutations 
might influence the sensitivity to EGFR-TKIs [22–24]. 
Hata et  al. [12] investigated the frequency of multiple 
drug-sensitive and drug-resistant mutations related with 
EGFR-TKIs in 783 NSCLC patients and found that 
eight patients who carried overlapping G719S and 
L858R mutations presented short PFS and a low ORR in 
response to gefitinib. In our study, we performed NGS, 
which included a panel of 483 cancer-related genes in 43 
patients using tissue samples that contained EGFR exon 
18–21 mutations. The results of NGS showed no sig-
nificant difference in the presence of uncommon EGFR 
mutations or other somatic mutations between the two 
genotypes. However, due to the small sample size for 
NGS analysis in the current study, we cannot make a con-
clusion that genetic heterogeneity of tumors with EGFR 
19 del or L858R mutations is not associated with differ-
ences in clinical response to EGFR-TKIs for the patients 

































































































































































































































































































EGFR 19 Del EGFR 21 SNP
Fig. 3 Heat map of 483 cancer‑related genes in 12 pairs of patients with the EGFR 19 del or L858R mutation. The red squares represent genes with a 
mutation, and the blue squares represent those with no mutation
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used and/or a prospective study should be conducted for 
further validation.
We also found that the appearance of MCL1 copy num-
ber variation was more frequent in patients with EGFR 
19 del compared with those harboring the L858R muta-
tion (10/12 vs. 4/12, P  =  0.04). MCL1 gene expression 
was thought to be significantly associated with chemo- 
and radio-resistance and poor prognosis among NSCLC 
patients [25]. In contrast, several studies have indicated 
that MCL1 overexpression was a protective factor against 
breast cancer and can reduce tumor cell proliferation and 
arrest cell cycle progression [26]. Due to the small sam-
ple size of patients and insufficient sequencing depth 
in the present study, we cannot draw a sound conclu-
sion that MCL1 contributes to the different outcomes of 
the patients with two distinct genotypes. Although the 
panel used in our study covered 483 genes, there exists 
a possibility that other key co-existing genetic alterations 
are not included in this panel. Therefore, genetic profiling 
on a larger scale, such as whole exon sequencing or whole 
genome sequencing, should be performed for the further 
analysis of other genes that may influence the different 
outcomes of the two genotypes.
In addition, our results indicated that the OS was 
similar in two subtype groups of patients treated with 
first-generation EGFR-TKIs, but significant difference 
in OS was observed in patients treated with the sec-
ond-generation EGFR-TKI afatinib in a previous study 
[10]. Unlike first-generation EGFR-TKIs, the second-
generation EGFR-TKI afatinib is an irreversible inhibi-
tor of EGFR and epidermal receptor 2 (Her-2) tyrosine 
kinase. Afatinib not only targets EGFR but also has an 
inhibitory effect on Her-2 [10]. The different drug tar-
gets may also contribute to differences in OS between 
Table 5 List of genes differentially expressed between the EGFR exon 19 deletion and exon 21 L858R mutation groups
a Analyzed by using Fisher’s exact test
Gene Chromosome Reference base Mutated base Mutation frequency P valuea
EGFR 19  
deletion
Exon 21 L858R  
mutation
Difference
EGFR 7 T – 0 1 1 0.000
PARP1 1 A G 0.583 0.083 0.5 0.027
SPEN 1 T C 0.417 0 0.417 0.037
SPEN 1 A G 0.417 0 0.417 0.037
IGF1R 15 GGT G 0.417 0 0.417 0.037
NOS3 7 C G 0.583 0 0.583 0.005
KMT2D 12 G A 0.417 0 0.417 0.037
IGF1R 15 G A 0.417 0 0.417 0.037
SUFU 10 G A 0.583 0.083 0.5 0.027
EP300 22 T C 0.583 0.083 0.5 0.027
SPEN 1 A G 0.417 0 0.417 0.037
ACVR1B 12 C T 0.417 0 0.417 0.037
FLT1 13 T C 0.417 0 0.417 0.037
IGF1R 15 T C 0.417 0 0.417 0.037
RARA 17 C T 0.417 0 0.417 0.037
CSF1R 5 G A 0.417 0 0.417 0.037
ZC3HAV1 7 G A 0.417 0 0.417 0.037
NOS3 7 T G 0.5 0 0.5 0.014
ATG9B 7 G T 0.583 0.083 0.5 0.027
PARP1 1 C G 0.583 0.083 0.5 0.027
Fig. 4 Copy number variation (CNV) of myeloid cell leukemia sequence 1 (MCL1) in 12 pairs of patients with the EGFR 19 del or L858R mutation. The 
red squares represent the gain of MCL1 CNV. The blank squares represent no gain or loss of MCL1 CNV
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patients treated with first- and second-generation 
EGFR-TKIs.
In conclusion, for patients with advanced lung adeno-
carcinoma, the use of first-line EGFR-TKIs in patients 
who harbored the EGFR 19 del might be associated with 
higher ORR and longer PFS compared with patients 
who carried the L858R mutation. Regardless of the use 
of EGFR-TKIs as a first-line, second-line, or greater 
treatment, there was no significant difference in the OS 
between the two mutation subgroups. We also found that 
there was no difference in genetic heterogeneity between 
these two mutation subtypes using the NGS technique.
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